SCHEMBL1182292

SCHEMBL1182292

Brc1ccc(-c2ccccc2)nc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LDHA P00338 1/20 0.52
NPC1 O15118 3/20 0.48
RAB9A P51151 3/20 0.48
NFKB1 P19838 2/20 0.48
NFKB2 Q00653 2/20 0.48
RELA Q04206 2/20 0.48
SMN1; SMN2 Q16637 2/20 0.48
MAPK1 P28482 2/20 0.48
ALDH1A1 P00352 2/20 0.48
CYP11B1 P15538 5/20 0.46
CYP11B2 P19099 5/20 0.46
HPGDS O60760 1/20 0.46
NLRP3 Q96P20 1/20 0.46
BAZ2B Q9UIF8 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.43
KDM4E B2RXH2 1/20 0.42
GABRA1 P14867 1/20 0.42
GABRG2 P18507 1/20 0.42
GABRB3 P28472 1/20 0.42
GABRA5 P31644 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12523554 0.96 MAPK1 (0.56) LDHANPC1RAB9ANFKB1NFKB2
SCHEMBL15747736 0.94 NPC1 (0.53) LDHANPC1RAB9ANFKB1NFKB2
SCHEMBL646630 0.89 CYP2A6 (0.50) LDHANPC1RAB9ANFKB1NFKB2
SCHEMBL19933574 0.88 NPC1 (0.52) LDHANPC1RAB9ANFKB1NFKB2
SCHEMBL2482041 0.86 HSD17B1 (0.47) LDHANPC1RAB9ANFKB1NFKB2
SCHEMBL1416706 0.86 NPC1 (0.55) NPC1RAB9ANFKB1NFKB2RELA
SCHEMBL9613082 0.85 NPC1 (0.63) LDHANPC1RAB9ANFKB1NFKB2
SCHEMBL2251228 0.85 NPC1 (0.63) LDHANPC1RAB9ANFKB1NFKB2
SCHEMBL13917369 0.84 HSD17B1 (0.48) LDHANPC1RAB9ANFKB1NFKB2
SCHEMBL787234 0.83 CYP11B1 (0.49) LDHANPC1RAB9ANFKB1NFKB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 494 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111499569-B Method for simultaneously synthesizing 5-bromo-2-phenylpyridine and 2- (4-bromophenyl) pyridine in one step without metal catalysis 华中科技大学 2021-05-14 CN claimed
CN-111499569-A Method for simultaneously synthesizing 5-bromo-2-phenylpyridine and 2- (4-bromophenyl) pyridine in one step without metal catalysis 华中科技大学 2020-08-07 CN claimed
JP-11171863-A None JP disclosed
EP-4683925-A1 MATERIALS FOR ORGANIC ELECTROLUMINESCENT DEVICES Merck Patent GmbH (DE) 2026-01-28 EP disclosed
US-20260015313-A1 AMINO ACID ACTIVE ESTER AND SALT THEREOF PEPTIDREAM INC (JP) 2026-01-15 US disclosed
US-20250353833-A1 DPP9 BINDING COMPOUNDS UNIV ANTWERPEN (BE) 2025-11-20 US disclosed
EP-4640022-A1 MATERIALS FOR ELECTRONIC DEVICES Merck Patent GmbH (DE) 2025-10-29 EP disclosed
US-20250257035-A1 1,4-Substituted Piperidine Derivatives CEPHALON LLC 2025-08-14 US disclosed
EP-4601449-A2 COMPOUNDS USABLE AS ACTIVE COMPOUNDS IN AN ORGANIC ELECTRONIC DEVICE Merck Patent GmbH (DE) 2025-08-13 EP disclosed
US-20250213560-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS HAVING PHENYL GROUP AND USES THEREOF BNH RESEARCH CO., LTD. (KR) 2025-07-03 US disclosed
EP-4190880-B1 COMPOUNDS USABLE AS ACTIVE COMPOUNDS IN AN ORGANIC ELECTRONIC DEVICE MERCK PATENT GMBH (DE) 2025-07-02 EP disclosed
EP-0979226-A1 ISOXAZOLE DERIVATIVES SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 2000-02-16 EP disclosed
JP-H11171863-A PHENYLPYRIDINYLBENZOIC ACID TRIFLUOROALKANOL ESTER AND LIQUID CRYSTAL COMPOSITION CHISSO CORP 1999-06-29 JP disclosed
WO-1998047880-A1 ISOXAZOLE DERIVATIVES SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 1998-10-29 WO disclosed
EP-0517365-B1 Method and apparatus for silicon nitride precursor solids recovery FORD MOTOR CO (GB) 1996-01-31 EP disclosed
EP-0674635-A1 QUINUCLIDINE DERIVATIVES AS SQUALENE SYNTHASE INHIBITORS ZENECA LIMITED (GB) 1995-10-04 EP disclosed
US-5403563-A Apparatus for silicon nitride precursor solids recovery FORD MOTOR COMPANY (US) 1995-04-04 US disclosed
WO-1994014803-A1 QUINUCLIDINE DERIVATIVES AS SQUALENE SYNTHASE INHIBITORS ZENECA LIMITED (GB) 1994-07-07 WO disclosed
US-5171557-A METHOD FOR SILICON NITRIDE PRECURSOR SOLIDS RECOVERY FORD MOTOR COMPANY (US) 1992-12-15 US disclosed
EP-0517365-A1 Method and apparatus for silicon nitride precursor solids recovery FORD MOTOR COMPANY LIMITED (GB) 1992-12-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250257035-A1 1,4-Substituted Piperidine Derivatives FASN, CES1, CPT1A LDHA 3251/4885NPC1 198/4885RAB9A 2624/4885
US-20260015313-A1 AMINO ACID ACTIVE ESTER AND SALT THEREOF NSUN3, BCAT1, SLC43A1 LDHA 1324/4885NPC1 1159/4885RAB9A 1211/4885
US-20250213560-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS HAVING PHENYL GROUP AND USES THEREOF PNMT, BDNF, NLN LDHA 1400/4885NPC1 1087/4885RAB9A 1763/4885
US-20250353833-A1 DPP9 BINDING COMPOUNDS DPP9, DPP7, DPP3 LDHA 865/4885NPC1 1617/4885RAB9A 1580/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.